Aphria Inc. (APHA)
(Delayed Data from NYSE)
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.94 USD
-0.19 (-2.66%)
Updated May 3, 2019 04:02 PM ET
After-Market: $7.00 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Abbott Stock Down on Urgent Field Safety Notice for TactiCath
by Zacks Equity Research
Abbott (ABT) also mentions certain guidelines related to product return, reporting, and customer assistance.
LabCorp's New Website Offers Patients Coronavirus Trial Details
by Zacks Equity Research
LabCorp's (LH) Covance business benefits from collaborations with leading pharmaceutical and biotechnology companies.
Here's Why You Should Retain Ecolab in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Ecolab (ECL) stock, thanks to solid prospects.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Teleflex (TFX) on robust segmental and geographical growth.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust segmental growth and regulatory approvals.
Why You Should Retain PerkinElmer (PKI) in Your Portfolio
by Zacks Equity Research
PerkinElmer (PKI) continues to gain traction from strong international presence and robust product portfolio.
Change Healthcare (CHNG) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance across the Network Solutions segment and higher revenues.
Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout
by Zacks Equity Research
Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.
Bruker Rides on PCI Sales, Coronavirus-Led Supply Issues Hurt
by Zacks Equity Research
Bruker (BRKR) expects a rise in sales within life science, biopharma and basic medical research, as well as in infectious disease diagnostics due to the pandemic.
HealthEquity (HQY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q1.
ABIOMED's (ABMD) Impella RP Receives FDA's EUA Clearance
by Zacks Equity Research
This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product portfolio.
Boston Scientific (BSX) Launches Monitoring Tool Post FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.
Cerner & NCHC Alliance to Boost Behavioral Health Technology
by Zacks Equity Research
Cerner (CERN) has been selected by NCHC to implement its EHR across three multi-specialty facilities.
Medtronic Alters ECMO Therapy on New FDA Rules for Coronavirus
by Zacks Equity Research
Medtronic (MDT), in response to the FDA's new guidance due to the coronavirus-led health emergency, has made temporary alterations to its cardiopulmonary product indications for use in ECMO therapy.
Tandem Diabetes Rides on Control-IQ Amid Coronavirus Crisis
by Zacks Equity Research
Strong domestic pump sales and international expansion boosts sales of Tandem Diabetes (TNDM).
Here's Why You Should Hold on to Tandem Diabetes Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Tandem Diabetes (TNDM) on robust pump sales and international growth.
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
NextGen's (NXGN) fiscal fourth-quarter 2020 results gain from strong Recurring revenues.
QIAGEN Sales Grow on Coronavirus Solutions Ahead of Selloff
by Zacks Equity Research
QIAGEN (QGEN) ramps up production capacity of solutions currently being used for testing purposes.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Thermo Fisher (TMO) Partners With CSL to Expand Pharma Arm
by Zacks Equity Research
Thermo Fisher (TMO), through its alliance with CSL, expands Pharma Services arm to meet the rising demand for biologic therapies.
Here's Why You Should Add Accuray to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter performance is likely to reflect better-than-expected performance at CVI and CSI.
Quest Diagnostics' Self-Collection Coronavirus Kit Gets EUA
by Zacks Equity Research
This kit by Quest Diagnostics (DGX) is suitable for use in children supervised by an adult.
Here's Why You Should Add DexCom (DXCM) to Your Portfolio
by Zacks Equity Research
DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.
LabCorp Partners With Medable to Expand Technology Ecosystem
by Zacks Equity Research
LabCorp (LH) expands technology ecosystem to accelerate the adoption of decentralized clinical trials by collaborating with Medable.